Viveve Medical (VIVE) 10-Q 10 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 09, 2018
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		31,269,388
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	[1]
Current assets:
Cash and cash equivalents	$ 38,378	$ 20,730
Accounts receivable, net of allowance for doubtful accounts of $263 and $221 as of March 31, 2018 and December 31, 2017, respectively	6,999	6,213
Inventory	3,828	2,390
Prepaid expenses and other current assets	3,302	2,741
Total current assets	52,507	32,074
Property and equipment, net	1,674	1,303
Investment in limited liability company	2,251	2,500
Other assets	204	202
Total assets	56,636	36,079
Current liabilities:
Accounts payable	3,865	4,799
Accrued liabilities	4,257	4,605
Total current liabilities	8,122	9,404
Note payable, noncurrent portion	29,334	28,948
Other noncurrent liabilities	218	327
Total liabilities	37,674	38,679
Commitments and contingences (Note 7)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 75,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 31,254,716 and 19,503,558 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	3	2
Additional paid-in capital	137,032	102,979
Accumulated deficit	(118,073)	(105,581)
Total stockholders’ equity (deficit)	18,962	(2,600)
Total liabilities and stockholders’ equity (deficit)	$ 56,636	$ 36,079
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	[1]
Accounts receivable, allowance for doubtful accounts	$ 263	$ 221
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	31,254,716	19,503,558
Common stock, shares outstanding (in shares)	31,254,716	19,503,558
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue	$ 3,699	$ 3,041
Cost of revenue	2,352	1,619
Gross profit	1,347	1,422
Operating expenses:
Research and development	3,756	2,388
Selling, general and administrative	8,931	5,450
Total operating expenses	12,687	7,838
Loss from operations	(11,340)	(6,416)
Interest expense, net	(1,070)	(263)
Other expense, net	(10)	(16)
Net loss from consolidated companies	(12,420)	(6,695)
Loss from minority interest in limited liability company	(249)
Comprehensive and net loss	$ (12,669)	$ (6,695)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.49)	$ (0.57)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	25,846,724	11,663,765

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018		Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (12,669)		$ (6,695)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	42
Depreciation and amortization	150		107
Stock-based compensation	753		372
Non-cash interest expense	386		35
Loss from minority interest in limited liability company	249
Changes in assets and liabilities:
Accounts receivable	(828)		(1,929)
Inventory	(1,497)		40
Prepaid expenses and other current assets	(561)		(174)
Other noncurrent assets	(2)		(16)
Accounts payable	(934)		273
Accrued and other liabilities	(366)		(99)
Other noncurrent liabilities	86		37
Net cash used in operating activities	(15,191)		(8,049)
Cash flows from investing activities:
Purchase of property and equipment	(462)		(151)
Net cash used in investing activities	(462)		(151)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	33,236		31,503
Proceeds from issuance of common shares from employee stock purchase plan	65
Net cash provided by financing activities	33,301		31,503
Net increase in cash and cash equivalents	17,648		23,303
Cash and cash equivalents - beginning of period	20,730	[1]	8,086
Cash and cash equivalents - end of period	38,378		31,389
Supplemental disclosure:
Cash paid for interest	653		194
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Issuance of note payable in settlement of accrued interest	305
Net transfer of equipment between inventory and property and equipment	$ 59		$ 264
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry in some countries by marketing the Viveve System and its Geneveve™ treatment as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity, depending on the relevant country-specific clearance or approval. Public Offering s On February 12, 2018, “February 2018 11,500,000 $3.00 $34,500,000. $32,225,000. The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, may $25,000,000 “November 2017 March 31, 2018, 208,277 November 2017 $1,011,000. March 31, 2018, 267,526 November 2017 $1,136,000. On March 22, 2017, “March 2017 8,625,000 $4.00 $34,500,000. $31,440,000. Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2017, March 16, 2018. three March 31, 2018 not December 31, 2018

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements. Adoption of New Accounting Standard On January 1, 2018, 606 606 606” not January 1, 2018. January 1, 2018 606, not 605 605” Previously under ASC 605, 606, not $177,000, $195,000 $18,000 The details for the impact of the adoption of ASC 606 Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 ) ( 1 Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606. ( 2 Change relates to long-term deferred revenue related to the extended warranties not 606. ( 3 Change relates to cumulative effect adjustment upon adoption of ASC 606. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no The Company’s products likely require clearance or approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, and for use in general surgical procedures for electrocoagulation and hemostasis, depending on the relevant country-specific clearance or approval, that it refers to as the Viveve System. The Viveve System consists of three four five third In North America., the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2018, two 54% three March 31, 2017, two 33% There were no 10% three March 31, 2018 2017. As of March 31, 2018, three 76% December 31, 2017, two 57% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $263,000 March 31, 2018 $221,000 December 31, 2017. Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2018 December 31, 2017. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one three March 31, 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the three March 31, 2018 March 31, 2018 For the Three Months Ended March 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Higher/(Lower) Consolidated Statement of Operations: Revenue $ 3,699 $ 3,489 $ 210 (1) Cost of revenue $ 2,352 $ 2,343 $ 9 (2) Gross profit $ 1,347 $ 1,146 $ 201 (3) Loss from operations $ (11,340 ) $ (11,541 ) $ 201 (3) Comprehensive and net loss $ (12,669 ) $ (12,870 ) $ 201 (3) Net loss per share: Basic and diluted $ (0.49 ) $ (0.50 ) $ 0.01 (3) ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of March 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Higher/(Lower) Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,257 $ 4,255 $ (2 ) (1) Other noncurrent liabilities $ 218 $ 598 $ 380 (2) Equity Accumulated deficit $ (118,073 ) $ (118,451 ) $ (378 ) (3) ( 1 Change relates to future costs associated with extended warranties required to be recorded on the adoption of ASC 606, not 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $201,000 three March 31, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area (in thousands): Three Months Ended March 31, 2018 2017 North America $ 2,606 $ 1,895 Asia Pacific 891 743 Europe and Middle East 202 113 Latin America - 290 Total $ 3,699 $ 3,041 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not three March 31, 2018, no Product Warranty The Company’s products are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2018 2017, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2018 2017 Stock options to purchase common stock 3,690,902 2,134,214 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards 22,500 12,500 Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no three March 31, 2018. $37,000 three March 31, 2017. Recently Issued and Adopted Accounting Standards In February 2016, 2016 02, 842 December 15, 2018, In August 2016, No. 2016 15, 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, 718 may 718. December 15, 2017, January 1, 2018 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no March 31, 2018 December 31, 2017. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 31, 2018 December 31, 2017 There were no

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not March 31, 2018, 2,100 $80,000 three March 31, 2018. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not March 31, 2018, 11% three three March 31, 2018, $249,000.

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued liabilities consisted of the following as of March 31, 2018 December 31, 2017 ( March 31, December 31, 2018 2017 Accrued professional fees $ 1,046 $ 562 Accrued sales commission 973 1,067 Accrued interest 651 447 Accrued payroll and other related expenses 507 488 Accrued bonuses 397 1,597 Travel and entertainment 223 156 Other accruals 460 288 Total accrued liabilities $ 4,257 $ 4,605

Note 6 - Note Payable

Note 6 - Note Payable	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	6. On June 20, 2016, January 13, 2017 ( “2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. 2016 4.00% 2016 May 2017. In connection with the 2016 10 100,402 $4.98 8 On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may The 2017 six four 2017 12.5%, 4.0% may, three March 31, 2018, $305,000 March 31, 2018. 5.0% March 31, 2018, $218,000 The Company may 2017 first five no As security for its obligations under the 2017 The terms of the 2017 $2.0 2022, not 2.0 2017 March 31, 2018, In connection with the 2017 two 10 222,049 $9.50 8 As of March 31, 2018, Year Ending December 31, 2018 (remaining nine months) $ 2,020 2019 2,778 2020 2,901 2021 16,672 2022 19,306 Thereafter 6,221 Total payments 49,898 Less: Amount representing interest (19,098 ) Present value of obligations 30,800 Less: Unamortized debt discount (1,466 ) Note payable, noncurrent portion $ 29,334

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Operating Lease In January 2012, March 2012 April 2018. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the three March 31, 2018 2017 $138,000 $73,000, As of March 31, 2018, Year Ending December 31, 2018 (remaining nine months) $ 221 2019 264 2020 112 Total minimum lease payments $ 597 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not Legal Proceedings On March 11, 2016, On October 20, 2017, two inter partes ‘511 ‘511 May 8, 2018, first one two second

Note 8 - Common Stock

Note 8 - Common Stock	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. On February 12, 2018, February 2018 11,500,000 $3.00 $34,500,000. $32,225,000. Through the November 2017 may $25,000,000 March 31, 2018, 208,277 November 2017 $1,012,000. March 31, 2018, 267,526 November 2017 $1,136,000. Warrants for Common Stock As of March 31, 2018, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622 In connection with the 2016 100,402 $4.98 $350,000. $90,000, May 2017 2017 June 30, 2017. three March 31, 2017, $35,000, In connection with the 2017 222,049, $9.50 ten $940,000 0%, 55.1%, 2.25% ten $786,000, three March 31, 2018, $77,000 March 31, 2018, $1,466,000. No three March 31, 2018 2017. No three March 31, 2018 2017. The stock-based compensation expense related to warrants issued was zero three March 31, 2018 2017.

Note 9 - Summary of Stock Optio

Note 9 - Summary of Stock Options	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards from two 2006 “2006 2013 “2013 As of March 31, 2018, 2006 38,378 no $10.49 4.63 On December 6, 2017, 2018 2013 914,016 4,000,000 4,914,016 January 1, 2018. As of March 31, 2018, 2013 3,652,524 1,069,228 $5.28 8.67 Activity under the 2005 2006 2013 Three Months Ended March 31, 2018 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 2,694,224 $ 5.80 8.58 $ 249,154 Options granted 1,253,559 $ 4.40 Options exercised - $ - Options canceled (256,881 ) $ 5.66 Options outstanding, end of period 3,690,902 $ 5.34 8.63 $ 12,750 Vested and exercisable and expected to vest, end of period 3,445,833 $ 5.36 8.57 $ 12,628 Vested and exercisable, end of period 1,006,199 $ 5.74 6.96 $ 9,297 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of March 31, 2018. The options outstanding and exercisable as of March 31, 2018 Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2018 Price Term (Years) March 31, 2018 Price $2.64 12,500 $ 2.64 7.12 9,115 $ 2.64 $3.66 - $3.82 171,876 $ 3.79 8.77 51,551 $ 3.76 $4.30 - $4.97 1,549,550 $ 4.52 9.22 270,103 $ 4.68 $5.01 - $5.67 912,800 $ 5.36 8.93 178,340 $ 5.22 $6.00 - $6.61 619,062 $ 6.06 7.21 345,227 $ 6.03 $7.00 - $7.92 386,736 $ 7.64 8.19 113,485 $ 7.71 $9.92 38,135 $ 9.92 4.65 38,135 $ 9.92 $59.60 - $149.04 243 $ 100.46 2.72 243 $ 100.46 3,690,902 $ 5.34 8.63 1,006,199 $ 5.74 Restricted Stock Awards In January 2018, 9,637 2013 $5.19 9,637 In January 2018, 25,000 $5.19 one March 31, 2018, 12,500 There are 22,500 March 31, 2018. 2017 The second 2017 “2017 January 1, 2018 March 31, 2018, 20,744 March 29, 2018 $3.11. March 31, 2018, 2017 361,362 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended March 31, 2018 Expected term (in years) 0.25 Average volatility 59% Risk-free interest rate 1.39% Dividend yield 0% The weighted average grant date fair value of the purchase rights issued under the 2017 three March 31, 2018 $1.30 Stock-Based Compensation During the three March 31, 2018 2017, 1,251,171 229,860 $2.77 $1.96 no three March 31, 2018 2017. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2018 2017 Expected term (in years) 5 5 Average volatility 76% 48% Risk-free interest rate 2.48% 2.02% Dividend yield 0% 0% During the three March 31, 2018, 2,388 $2.98. three March 31, 2017, no no three March 31, 2018 2017. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2018 Expected term (in years) 9.81 Average volatility 77% Risk-free interest rate 2.73% Dividend yield 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three March 31, 2018 2017 Three Months Ended March 31, 2018 2017 Cost of revenue $ 11 $ 3 Research and development 122 51 Selling, general and administrative 620 318 Total $ 753 $ 372 As of March 31, 2018, $6,391,000. 3.16

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three March 31, 2018 2017. 2018 0%. On December 22, 2017, 21%, January 1, 2018.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. In June 2006, October 4, 2007. 300 March 31, 2018, 601 37,500 $3,273,000 $2,025,000 three March 31, 2018 2017, March 31, 2018 December 31, 2017 $1,129,000 $938,000, In connection with the Distributorship Agreement entered into with ICM, the Company also entered into a Membership Unit Subscription Agreement with ICM and the Company invested $2,500,000 March 31, 2018, 2,100 $80,000 three March 31, 2018. March 31, 2018 December 31, 2017 $26,000 $28,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Changes in Accounting Policies, Policy [Policy Text Block]	Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements. Adoption of New Accounting Standard On January 1, 2018, 606 606 606” not January 1, 2018. January 1, 2018 606, not 605 605” Previously under ASC 605, 606, not $177,000, $195,000 $18,000 The details for the impact of the adoption of ASC 606 Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 ) ( 1 Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606. ( 2 Change relates to long-term deferred revenue related to the extended warranties not 606. ( 3 Change relates to cumulative effect adjustment upon adoption of ASC 606.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no The Company’s products likely require clearance or approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, and for use in general surgical procedures for electrocoagulation and hemostasis, depending on the relevant country-specific clearance or approval, that it refers to as the Viveve System. The Viveve System consists of three four five third In North America., the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2018, two 54% three March 31, 2017, two 33% There were no 10% three March 31, 2018 2017. As of March 31, 2018, three 76% December 31, 2017, two 57%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $263,000 March 31, 2018 $221,000 December 31, 2017.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2018 December 31, 2017. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one three March 31, 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the three March 31, 2018 March 31, 2018 For the Three Months Ended March 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Higher/(Lower) Consolidated Statement of Operations: Revenue $ 3,699 $ 3,489 $ 210 (1) Cost of revenue $ 2,352 $ 2,343 $ 9 (2) Gross profit $ 1,347 $ 1,146 $ 201 (3) Loss from operations $ (11,340 ) $ (11,541 ) $ 201 (3) Comprehensive and net loss $ (12,669 ) $ (12,870 ) $ 201 (3) Net loss per share: Basic and diluted $ (0.49 ) $ (0.50 ) $ 0.01 (3) ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of March 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Higher/(Lower) Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,257 $ 4,255 $ (2 ) (1) Other noncurrent liabilities $ 218 $ 598 $ 380 (2) Equity Accumulated deficit $ (118,073 ) $ (118,451 ) $ (378 ) (3) ( 1 Change relates to future costs associated with extended warranties required to be recorded on the adoption of ASC 606, not 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $201,000 three March 31, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area (in thousands): Three Months Ended March 31, 2018 2017 North America $ 2,606 $ 1,895 Asia Pacific 891 743 Europe and Middle East 202 113 Latin America - 290 Total $ 3,699 $ 3,041 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not three March 31, 2018, no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to warranties between one three not
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2018 2017,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2018 2017 Stock options to purchase common stock 3,690,902 2,134,214 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards 22,500 12,500
Reclassification, Policy [Policy Text Block]	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no three March 31, 2018. $37,000 three March 31, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In February 2016, 2016 02, 842 December 15, 2018, In August 2016, No. 2016 15, 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, 718 may 718. December 15, 2017, January 1, 2018 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa18

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block]	Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 )
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	For the Three Months Ended March 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Higher/(Lower) Consolidated Statement of Operations: Revenue $ 3,699 $ 3,489 $ 210 (1) Cost of revenue $ 2,352 $ 2,343 $ 9 (2) Gross profit $ 1,347 $ 1,146 $ 201 (3) Loss from operations $ (11,340 ) $ (11,541 ) $ 201 (3) Comprehensive and net loss $ (12,669 ) $ (12,870 ) $ 201 (3) Net loss per share: Basic and diluted $ (0.49 ) $ (0.50 ) $ 0.01 (3) As of March 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Higher/(Lower) Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,257 $ 4,255 $ (2 ) (1) Other noncurrent liabilities $ 218 $ 598 $ 380 (2) Equity Accumulated deficit $ (118,073 ) $ (118,451 ) $ (378 ) (3)
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended March 31, 2018 2017 North America $ 2,606 $ 1,895 Asia Pacific 891 743 Europe and Middle East 202 113 Latin America - 290 Total $ 3,699 $ 3,041
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2018 2017 Stock options to purchase common stock 3,690,902 2,134,214 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards 22,500 12,500

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2018 2017 Accrued professional fees $ 1,046 $ 562 Accrued sales commission 973 1,067 Accrued interest 651 447 Accrued payroll and other related expenses 507 488 Accrued bonuses 397 1,597 Travel and entertainment 223 156 Other accruals 460 288 Total accrued liabilities $ 4,257 $ 4,605

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2018 (remaining nine months) $ 2,020 2019 2,778 2020 2,901 2021 16,672 2022 19,306 Thereafter 6,221 Total payments 49,898 Less: Amount representing interest (19,098 ) Present value of obligations 30,800 Less: Unamortized debt discount (1,466 ) Note payable, noncurrent portion $ 29,334

Note 7 - Commitments and Cont21

Note 7 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2018 (remaining nine months) $ 221 2019 264 2020 112 Total minimum lease payments $ 597

Note 8 - Common Stock (Tables)

Note 8 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622

Note 9 - Summary of Stock Opt23

Note 9 - Summary of Stock Options (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Three Months Ended March 31, 2018 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 2,694,224 $ 5.80 8.58 $ 249,154 Options granted 1,253,559 $ 4.40 Options exercised - $ - Options canceled (256,881 ) $ 5.66 Options outstanding, end of period 3,690,902 $ 5.34 8.63 $ 12,750 Vested and exercisable and expected to vest, end of period 3,445,833 $ 5.36 8.57 $ 12,628 Vested and exercisable, end of period 1,006,199 $ 5.74 6.96 $ 9,297
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2018 Price Term (Years) March 31, 2018 Price $2.64 12,500 $ 2.64 7.12 9,115 $ 2.64 $3.66 - $3.82 171,876 $ 3.79 8.77 51,551 $ 3.76 $4.30 - $4.97 1,549,550 $ 4.52 9.22 270,103 $ 4.68 $5.01 - $5.67 912,800 $ 5.36 8.93 178,340 $ 5.22 $6.00 - $6.61 619,062 $ 6.06 7.21 345,227 $ 6.03 $7.00 - $7.92 386,736 $ 7.64 8.19 113,485 $ 7.71 $9.92 38,135 $ 9.92 4.65 38,135 $ 9.92 $59.60 - $149.04 243 $ 100.46 2.72 243 $ 100.46 3,690,902 $ 5.34 8.63 1,006,199 $ 5.74
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2018 2017 Expected term (in years) 5 5 Average volatility 76% 48% Risk-free interest rate 2.48% 2.02% Dividend yield 0% 0% Three Months Ended March 31, 2018 Expected term (in years) 9.81 Average volatility 77% Risk-free interest rate 2.73% Dividend yield 0%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended March 31, 2018 2017 Cost of revenue $ 11 $ 3 Research and development 122 51 Selling, general and administrative 620 318 Total $ 753 $ 372
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2018 Expected term (in years) 0.25 Average volatility 59% Risk-free interest rate 1.39% Dividend yield 0%

Note 1 - The Company and Basi24

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Feb. 12, 2018	Nov. 08, 2017	Mar. 22, 2017	Mar. 31, 2018	Mar. 31, 2017
Proceeds from Issuance of Common Stock				$ 33,236,000	$ 31,503,000
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	11,500,000
Share Price	$ 3
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 32,225,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues				267,526
Proceeds From Issuance of Common Stock, Net				$ 1,136,000
Aggregate Offering Price		$ 25,000,000
ATM Facility [Member]
Stock Issued During Period, Shares, New Issues				208,277
Proceeds From Issuance of Common Stock, Net				$ 1,011,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues			8,625,000
Share Price			$ 4
Proceeds from Issuance of Common Stock			$ 34,500,000
Proceeds From Issuance of Common Stock, Net			$ 31,440,000

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended		12 Months Ended
		Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)		Jan. 01, 2018USD ($)
Retained Earnings (Accumulated Deficit), Ending Balance		$ (118,073,000)		$ (105,581,000)	[1]	$ (105,404,000)
Other Liabilities, Noncurrent, Total		218,000		327,000	[1]	132,000
Accrued Liabilities, Current, Total		$ 4,257,000		4,605,000	[1]	$ 4,623,000
Number of Financial Institutions		1
Allowance for Doubtful Accounts Receivable, Ending Balance		$ 263,000		221,000
Contract with Customer, Liability, Total		0		0
Gross Profit, Total		1,347,000	$ 1,422,000
Equity Method Investment, Other than Temporary Impairment		$ 0
Warranty Period		1 year
Contract with Customer, Asset, Net, Total		$ 0		$ 0
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Customers		2	2	2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Three Customers [Member]
Concentration Risk, Percentage		54.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two Customers [Member]
Concentration Risk, Percentage			33.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers		3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage		76.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage				57.00%
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance	[2]			$ 177,000
Other Liabilities, Noncurrent, Total	[3]			(195,000)
Accrued Liabilities, Current, Total	[4]			$ 18,000
Gross Profit, Total		$ 201,000
Increase in Change Amount Reported for Accrued and Other Liabilities Due To Separate Disclosure of Change in Other Noncurrent Liabilities [Member] | Quarter Ended March 31, 2017 [Member]
Prior Period Reclassification Adjustment		$ 37,000
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.
[2]	Change relates to cumulative effect adjustment upon adoption of ASC 606.
[3]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[4]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($)		Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Liabilities
Accrued liabilities		$ 4,257,000	$ 4,623,000	$ 4,605,000	[1]
Other noncurrent liabilities		218,000	132,000	327,000	[1]
Stockholders’ equity (deficit):
Accumulated deficit		$ (118,073,000)	$ (105,404,000)	(105,581,000)	[1]
Accounting Standards Update 2014-09 [Member]
Liabilities
Accrued liabilities	[2]			18,000
Other noncurrent liabilities	[3]			(195,000)
Stockholders’ equity (deficit):
Accumulated deficit	[4]			$ 177,000
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.
[2]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.
[3]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[4]	Change relates to cumulative effect adjustment upon adoption of ASC 606.

Note 2 - Summary of Significa27

Note 2 - Summary of Significant Accounting Policies - Impact of New Standard on Consolidated Balance Sheet and Consolidated Statements of Operations (Details) - USD ($)		3 Months Ended
		Mar. 31, 2018	Mar. 31, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenue		$ 3,699,000	$ 3,041,000
Cost of revenue		2,352,000	1,619,000
Gross profit		1,347,000	1,422,000
Loss from operations		(11,340,000)	(6,416,000)
Comprehensive and net loss		$ (12,669,000)	$ (6,695,000)
Basic and diluted (in dollars per share)		$ (0.49)	$ (0.57)
Liabilities
Accrued liabilities		$ 4,257,000		$ 4,623,000	$ 4,605,000	[1]
Other noncurrent liabilities		218,000		132,000	327,000	[1]
Stockholders’ equity (deficit):
Accumulated deficit		(118,073,000)		$ (105,404,000)	(105,581,000)	[1]
Accounting Standards Update 2014-09 [Member]
Gross profit		201,000
Liabilities
Accrued liabilities	[2]				18,000
Other noncurrent liabilities	[3]				(195,000)
Stockholders’ equity (deficit):
Accumulated deficit	[4]				$ 177,000
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue		3,489,000
Cost of revenue		2,343,000
Gross profit		1,146,000
Loss from operations		(11,541,000)
Comprehensive and net loss		$ (12,870,000)
Basic and diluted (in dollars per share)		$ (0.50)
Liabilities
Accrued liabilities		$ 4,255,000
Other noncurrent liabilities		598,000
Stockholders’ equity (deficit):
Accumulated deficit		(118,451,000)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue	[5]	210,000
Cost of revenue	[6]	9,000
Gross profit	[7]	201,000
Loss from operations	[7]	201,000
Comprehensive and net loss	[7]	$ 201,000
Basic and diluted (in dollars per share)	[7]	$ 0.01
Liabilities
Accrued liabilities	[8]	$ (2,000)
Other noncurrent liabilities	[9]	380,000
Stockholders’ equity (deficit):
Accumulated deficit	[10]	$ (378,000)
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.
[2]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.
[3]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[4]	Change relates to cumulative effect adjustment upon adoption of ASC 606.
[5]	Change relates to revenue from extended assurance warranties for which no deferral is required on the adoption of ASC 606.
[6]	Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606.
[7]	Change relates to the net gain adjustment on the adoption of ASC 606.
[8]	Change relates to future costs associated with extended warranties required to recorded on the adoption of ASC 606, partially offset by the current portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606.
[9]	Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606.
[10]	Change relates to $177,000 cumulative effect adjustment on the adoption of ASC 606 and the net gain adjustment of $201,000 for the three months ended March 31, 2018.

Note 2 - Summary of Significa28

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue	$ 3,699	$ 3,041
North America [Member]
Revenue	2,606	1,895
Asia Pacific [Member]
Revenue	891	743
Europe And Middle East [Member]
Revenue	202	113
Latin America [Member]
Revenue		$ 290

Note 2 - Summary of Significa29

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Stock Option [Member]
Stock options to purchase common stock (in shares)	3,690,902	2,134,214
Common Stock Warrants [Member]
Stock options to purchase common stock (in shares)	642,622	425,274
Restricted Stock [Member]
Stock options to purchase common stock (in shares)	22,500	12,500

Note 4 - Investment in Limite30

Note 4 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)
Income (Loss) from Equity Method Investments, Total		$ (249,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		11.00%
Income (Loss) from Equity Method Investments, Total		$ (249,000)
InControl Medical [Member] | Distribution Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		2,100
Payments for Purchase of Products		$ 80,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000	$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Accrued professional fees	$ 1,046		$ 562
Accrued sales commission	973		1,067
Accrued interest	651		447
Accrued payroll and other related expenses	507		488
Accrued bonuses	397		1,597
Travel and entertainment	223		156
Other accruals	460		288
Total accrued liabilities	$ 4,257	$ 4,623	$ 4,605	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	May 22, 2017	Jun. 20, 2016	Mar. 31, 2018
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			642,622
Class of Warrant or Right, Exercise Price of Warrants or Rights
Interest Payable			$ 19,098,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Warrant Term		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		100,402	100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.98	$ 4.98
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrant Term	10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049		222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50		$ 9.50
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount		$ 10,000,000
Debt Instrument, Fee, Percentage		4.00%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | First Tranche [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 7,500,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Second Tranche [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 2,500,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount	$ 20,000,000
Debt Agreement, Covenant, Additional Funding	10,000,000
Debt Agreement, Maximum Borrowing Capacity	$ 30,000,000
Debt Instrument, Term	6 years
Debt instrument, Interest Only Payment, Period	4 years
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period	4.00%
Paid-in-Kind Interest			$ 305,000
Debt Instrument, Prepayment Fee, Percentage	5.00%
Debt Instrument, Prepayment Fee, Period of Term	5 years
Debt Instrument, Covenant, Cash and Cash Equivalents	$ 2,000,000
The 2017 Loan Agreement [Member] | CRG LP [Member] | Other Noncurrent Liabilities [Member]
Interest Payable			$ 218,000

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	[1]
2018 (remaining nine months)	$ 2,020
2,019	2,778
2,020	2,901
2,021	16,672
2,022	19,306
Thereafter	6,221
Total payments	49,898
Less: Amount representing interest	(19,098)
Present value of obligations	30,800
Less: Unamortized debt discount	(1,466)
Note payable, noncurrent portion	$ 29,334	$ 28,948
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Commitments and Cont34

Note 7 - Commitments and Contingencies (Details Textual)	3 Months Ended
	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Feb. 01, 2017USD ($)ft²$ / item
Operating Leases, Rent Expense, Total | $	$ 138,000	$ 73,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²			12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / item			20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / item			21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / item			21.75
Security Deposit | $			$ 22,000
Operating Leases, Allowance for Certain Improvements | $			$ 88,000

Note 7 - Commitments and Cont35

Note 7 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2018USD ($)
2018 (remaining nine months)	$ 221
2,019	264
2,020	112
Total minimum lease payments	$ 597

Note 8 - Common Stock (Details

Note 8 - Common Stock (Details Textual)	Feb. 12, 2018USD ($)$ / sharesshares	Nov. 08, 2017USD ($)	May 22, 2017USD ($)$ / sharesshares	Jun. 20, 2016USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Mar. 31, 2017USD ($)shares
Proceeds from Issuance of Common Stock					$ 33,236,000	$ 31,503,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					642,622
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares
Debt Instrument, Unamortized Discount, Total					$ 1,466,000
Class of Warrants or Rights, Exercises in Period | shares					0	0
Allocated Share-based Compensation Expense, Total					$ 753,000	$ 372,000
The 2016 Loan Agreement [Member]
Debt Issuance Costs, Net, Total				$ 90,000
Amortization of Debt Discount (Premium)						35,000
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total					786,000
Amortization of Debt Discount (Premium)					77,000
Debt Instrument, Unamortized Discount, Total					$ 1,466,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				100,402	100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 4.98	$ 4.98
Warrants and Rights Outstanding				$ 350,000
Warrant Term				10 years
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			222,049		222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 9.50		$ 9.50
Warrants and Rights Outstanding			$ 940,000
Warrant Term			10 years
Allocated Share-based Compensation Expense, Total					$ 0	$ 0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			55.1
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			2.25
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input			10
Vendors and Contractors Warrants, October and November 2014 Issuance [Member]
Class of Warrants or Rights, Exercises in Period | shares					0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period | shares						0
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares	11,500,000
Share Price | $ / shares	$ 3
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 32,225,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues | shares					267,526
Proceeds From Issuance of Common Stock, Net					$ 1,136,000
Aggregate Offering Price		$ 25,000,000
ATM Facility [Member]
Stock Issued During Period, Shares, New Issues | shares					208,277
Proceeds From Issuance of Common Stock, Net					$ 1,011,000

Note 8 - Common Stock - Summary

Note 8 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	May 22, 2017	Jun. 20, 2016
Exercise Price (in dollars per share)
Shares Outstanding Under Warrants (in shares)	642,622
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	86,831
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4
Shares Outstanding Under Warrants (in shares)	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2.72
Shares Outstanding Under Warrants (in shares)	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5.60
Shares Outstanding Under Warrants (in shares)	26,875
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6.08
Shares Outstanding Under Warrants (in shares)	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7.74
Shares Outstanding Under Warrants (in shares)	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4.98		$ 4.98
Shares Outstanding Under Warrants (in shares)	100,402		100,402
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9.50	$ 9.50
Shares Outstanding Under Warrants (in shares)	222,049	222,049

Note 9 - Summary of Stock Opt38

Note 9 - Summary of Stock Options (Details Textual) - USD ($)	Mar. 29, 2018	Dec. 06, 2017	Jan. 31, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 05, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance				3,690,902		2,694,224
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance				$ 5.34		$ 5.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				8 years 229 days		8 years 211 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,253,559
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options				$ 6,391,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				3 years 58 days
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance				38,378
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance				$ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				4 years 229 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance				3,652,524
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance				$ 5.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				8 years 244 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		914,016
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		4,914,016					4,000,000
Common Stock, Capital Shares Reserved for Future Issuance				1,069,228
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				2,388	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 2.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance				22,500
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				9,637
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 5.19
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			9,637
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 5.19
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			12,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year
2017 Employee Stock Purchase Plan [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	20,744
Employee Stock Purchase Plan, Purchase Price				$ 3.11
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares	361,362
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
2017 Employee Stock Purchase Plan [Member] | Weighted Average [Member]
Share Price				$ 1.30
2017 Employee Stock Purchase Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,251,171	229,860
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 2.77	$ 1.96
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				0	0

Note 9 - Summary of Stock Opt39

Note 9 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Options outstanding, Shares (in shares)	2,694,224
Options outstanding, Weighted average exercise price (in dollars per share)	$ 5.34	$ 5.80
Options outstanding, Weighted Average Remaining Contractual Term (Year)	8 years 229 days	8 years 211 days
Options outstanding, Aggregate Intrinsic Value	$ 12,750	$ 249,154
Options granted, Shares (in shares)	1,253,559
Options granted, Weighted average exercise price (in dollars per share)	$ 4.40
Options exercised, Shares (in shares)
Options exercised, Weighted average exercise price (in dollars per share)
Options canceled (in shares)	(256,881)
Options canceled, Weighted average exercise price (in dollars per share)	$ 5.66
Options outstanding, Shares (in shares)	3,690,902	2,694,224
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares)	3,445,833
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share)	$ 5.36
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 208 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value	$ 12,628
Vested and exercisable, end of period, Number Of Shares (in shares)	1,006,199
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share)	$ 5.74
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	6 years 350 days
Vested and exercisable, end of period, Aggregate Intrinsic Value	$ 9,297

Note 9 - Summary of Stock Opt40

Note 9 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Options outstanding, number (in shares) | shares	3,690,902
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.34
Options outstanding, weighted average remaining contractual term (Year)	8 years 229 days
Options exercisable, number exercisable (in shares) | shares	1,006,199
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.74
Range One [Member]
Exercise price range, lower limit (in dollars per share)	2.64
Exercise price range, upper limit (in dollars per share)	$ 2.64
Options outstanding, number (in shares) | shares	12,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.64
Options outstanding, weighted average remaining contractual term (Year)	7 years 43 days
Options exercisable, number exercisable (in shares) | shares	9,115
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	3.66
Exercise price range, upper limit (in dollars per share)	$ 3.82
Options outstanding, number (in shares) | shares	171,876
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.79
Options outstanding, weighted average remaining contractual term (Year)	8 years 281 days
Options exercisable, number exercisable (in shares) | shares	51,551
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.76
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	4.30
Exercise price range, upper limit (in dollars per share)	$ 4.97
Options outstanding, number (in shares) | shares	1,549,550
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.52
Options outstanding, weighted average remaining contractual term (Year)	9 years 80 days
Options exercisable, number exercisable (in shares) | shares	270,103
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.68
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	5.01
Exercise price range, upper limit (in dollars per share)	$ 5.67
Options outstanding, number (in shares) | shares	912,800
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.36
Options outstanding, weighted average remaining contractual term (Year)	8 years 339 days
Options exercisable, number exercisable (in shares) | shares	178,340
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.22
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	6
Exercise price range, upper limit (in dollars per share)	$ 6.61
Options outstanding, number (in shares) | shares	619,062
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.06
Options outstanding, weighted average remaining contractual term (Year)	7 years 76 days
Options exercisable, number exercisable (in shares) | shares	345,227
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.03
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Options outstanding, number (in shares) | shares	386,736
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.64
Options outstanding, weighted average remaining contractual term (Year)	8 years 69 days
Options exercisable, number exercisable (in shares) | shares	113,485
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.71
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	9.92
Exercise price range, upper limit (in dollars per share)	$ 9.92
Options outstanding, number (in shares) | shares	38,135
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	4 years 237 days
Options exercisable, number exercisable (in shares) | shares	38,135
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	59.60
Exercise price range, upper limit (in dollars per share)	$ 149.04
Options outstanding, number (in shares) | shares	243
Options outstanding, weighted average exercise price (in dollars per share)	$ 100.46
Options outstanding, weighted average remaining contractual term (Year)	2 years 262 days
Options exercisable, number exercisable (in shares) | shares	243
Options exercisable, weighted average exercise price (in dollars per share)	$ 100.46

Note 9 - Summary of Stock Opt41

Note 9 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Expected term (in years) (Year)	5 years	5 years
Average volatility	76.00%	48.00%
Risk-free interest rate	2.48%	2.02%
Dividend yield	0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (in years) (Year)	91 days
Average volatility	59.00%
Risk-free interest rate	1.39%
Dividend yield	0.00%

Note 9 - Summary of Stock Opt42

Note 9 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Expected term (in years) (Year)	5 years	5 years
Average volatility	76.00%	48.00%
Risk-free interest rate	2.48%	2.02%
Dividend yield	0.00%	0.00%
Nonemployees [Member]
Expected term (in years) (Year)	9 years 295 days
Average volatility	77.00%
Risk-free interest rate	2.73%
Dividend yield	0.00%

Note 9 - Summary of Stock Opt43

Note 9 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Allocated share-based compensation expense	$ 753	$ 372
Cost of Sales [Member]
Allocated share-based compensation expense	11	3
Research and Development Expense [Member]
Allocated share-based compensation expense	122	51
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 620	$ 318

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total			0.00%

Note 11 - Related Party Trans45

Note 11 - Related Party Transactions (Details Textual) - USD ($)	Aug. 08, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Dec. 31, 2017
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000	$ 2,500,000
Stellartech Research Corporation [Member]
Stock Issued During Period, Shares, New Issues				37,500
Related Party Transaction, Amounts of Transaction		3,273,000	$ 2,025,000
Accounts Payable, Related Parties, Current		1,129,000		$ 1,129,000	$ 938,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Related Party Transaction, Amounts of Transaction		80,000
Accounts Payable, Related Parties, Current		$ 26,000		$ 26,000	$ 28,000